COMBINING TO CURE^®

Arcus is at the forefront of designing precision combinations in the pursuit of cures for patients living with cancer.

We’re combining
therapeutic strategies

to activate the immune system to recognize and eradicate cancer, which we believe has the potential to achieve cures that have eluded medicine for decades.

We’re combining
our expertise

across scientific disciplines to discover innovative, best-in-class medicines and to design combination therapies guided by specific biologic profiles of cancer.

We’re combining with the medical community

and with patients and their caregivers to facilitate participation in our clinical trials and bring breakthrough medicines to patients faster.

Joining forces to defeat cancer.
This is COMBINING TO CURE^®

Arcus clinical trials are currently enrolling

Learn More

Join forces with us on our mission to defeat cancer

Learn More

Read our latest press releases and announcements

Learn More

CLINICAL PIPELINE

Indication View

Molecule View

Indication

Study

Line & Regimen^a,b,c

Indication:

NSCLC

Study: 
                                                
Line & Regimena,b,c : 
                                    1L, PD-L1 ≥ 50%
                                    
                                                                dom + zim ± etruma vs. zim
                                
Phase 1 
Phase 1b 
                                    
Randomized/
Phase 2
Pivotal/
Phase 3
Study: 
                                                        
Line & Regimena,b,c : 

                                            1L, 2L
                                                                                            
                                                                                        dom + zim ± quemli ± chemo 
                                        
Phase 1 
Phase 1b 
                                            
Randomized/
Phase 2
Pivtotal/
Phase 3
Study: 
                                                        
Line & Regimena,b,c : 

                                            1L, 2L
                                                                                            
                                                                                        dom ± zim ± etruma ± sacituzumab govitecan
                                        
Phase 1 
Phase 1b 
                                            
Randomized/
Phase 2
Pivtotal/
Phase 3
Study: 
                                                        
Line & Regimena,b,c : 

                                            1L, PD-L1 ≥ 50%
                                                                                            
                                                                                        dom + zim vs. pembro
                                        
Phase 1 
Phase 1b 
                                            
Randomized/
Phase 2
Pivotal/
Phase 3
Study: 
                                                        
Line & Regimena,b,c : 

                                            Stage III, unresectable, PD‑L1 ≥ 1%
                                                                                            
                                                                                        dom + durvalumab vs. durvalumab
                                        
Phase 1 
Phase 1b 
                                            
Randomized/
Phase 2
Pivotal/
Phase 3
Study: 
                                                        
Line & Regimena,b,c : 

                                            1L
                                                                                            
                                                                                        dom + zim + chemo vs. pembro + chemo
                                        
Phase 1 
Phase 1b 
                                            
Randomized/
Phase 2
Pivotal/
Phase 3

Indication:

mCRPC

Study:

Line & Regimen^a,b,c :

2L+
etruma + zim + doce vs. doce etruma + sacituzumab govitecan ± zim

Phase 1

Phase 1b

Randomized/
Phase 2

Pivotal/
Phase 3

Indication:

CRC

Study:

Line & Regimen^a,b,c :

2L
etruma + zim + FOLFOX* vs. FOLFOX*

Phase 1

Phase 1b

Randomized/
Phase 2

Pivotal/
Phase 3

Study:

Line & Regimen^a,b,c :

3L
etruma + zim + FOLFOX* vs. rego

Phase 1

Phase 1b

Randomized/
Phase 2

Pivtotal/
Phase 3

Indication:

PDAC

Study:

Line & Regimen^a,b,c :

1L
quemli + zim + gem/nab-pac vs. quemli + gem/nab-pac

Phase 1

Phase 1b

Randomized/
Phase 2

Pivotal/
Phase 3

Study:

Line & Regimen^a,b,c :

2L
quemli + zim + gem/nab-pac

Phase 1

Phase 1b

Randomized/
Phase 2

Pivtotal/
Phase 3

Indication:

UPPER GI

Study: 
                                                
Line & Regimena,b,c : 
                                    1L
                                    
                                                                dom + zim + FOLFOX*
                                
Phase 1 
Phase 1b 
                                    
Randomized/
Phase 2
Pivotal/
Phase 3
Study: 
                                                        
Line & Regimena,b,c : 

                                            2L+
                                                                                            
                                                                                        dom + zim
                                        
Phase 1 
Phase 1b 
                                            
Randomized/
Phase 2
Pivtotal/
Phase 3
Study: 
                                                        
Line & Regimena,b,c : 

                                            1L
                                                                                            
                                                                                        dom + zim + chemo vs.
nivo + chemo
                                        
Phase 1 
Phase 1b 
                                            
Randomized/
Phase 2
Pivotal/
Phase 3

Indication:

Advanced Malignancies

Study:

Line & Regimen^a,b,c :

2L+
AB521

Phase 1

Phase 1b

Randomized/
Phase 2

Pivotal/
Phase 3

Indication:

Healthy Participants

Study:

Line & Regimen^a,b,c :

AB521

Phase 1

Phase 1b

Randomized/
Phase 2

Pivotal/
Phase 3

Molecule^a,b,c :

Domvanalimab
(DOM)

FC-SILENT ANTI-TIGIT ANTIBODY

Indication:NSCLC
Study:
                                                
Line & Regimen:
                                    1L, PD-L1 ≥ 50%
                                                                            
                                                                        dom + zim ± etruma vs. zim
                                
Phase 1
Phase 1b
                                    
Phase 2
Phase 3
Indication:NSCLC
Study:
                                                        
Line & Regimen:

                                            1L, 2L
                                                                                            
                                                                                        dom + zim ± quemli ± chemo
                                        
Phase 1
Phase 1b
                                            
Phase 2
Phase 3
Indication:NSCLC
Study:
                                                        
Line & Regimen:

                                            1L, 2L 
                                                                                            
                                                                                        dom ± zim ± etruma ± sacituzumab govitecan
                                        
Phase 1
Phase 1b
                                            
Phase 2
Phase 3
Indication:NSCLC
Study:
                                                        
Line & Regimen:

                                            1L, PD-L1 ≥ 50%
                                                                                            
                                                                                        dom + zim vs. pembro
                                        
Phase 1
Phase 1b
                                            
Phase 2
Phase 3
Indication:NSCLC
Study:
                                                        
Line & Regimen:

                                            Stage III, unresectable, PD‑L1 ≥ 1%
                                                                                            
                                                                                        dom + durvalumab vs. durvalumab
                                        
Phase 1
Phase 1b
                                            
Phase 2
Phase 3
Indication:NSCLC
Study:
                                                        
Line & Regimen:

                                            1L
                                                                                            
                                                                                        dom + zim + chemo vs. pembro + chemo
                                        
Phase 1
Phase 1b
                                            
Phase 2
Phase 3
Indication:UPPER GI
Study:
                                                        
Line & Regimen:

                                            1L
                                                                                            
                                                                                        dom + zim + FOLFOX*
                                        
Phase 1
Phase 1b
                                            
Phase 2
Phase 3
Indication:UPPER GI
Study:
                                                        
Line & Regimen:

                                            2L+
                                                                                            
                                                                                        dom + zim
                                        
Phase 1
Phase 1b
                                            
Phase 2
Phase 3
Indication:UPPER GI
Study:
                                                        
Line & Regimen:

                                            1L
                                                                                            
                                                                                        dom + zim + chemo vs.
nivo + chemo
                                        
Phase 1
Phase 1b
                                            
Phase 2
Phase 3

Molecule^a,b,c :

Quemliclustat

CD73 Inhibitor Small Molecule

Indication:NSCLC
Study:
                                                
Line & Regimen:
                                    1L, 2L
                                                                            
                                                                        dom + zim ± quemli ± chemo
                                
Phase 1
Phase 1b
                                    
Phase 2
Phase 3
Indication:PDAC
Study:
                                                        
Line & Regimen:

                                            1L
                                                                                            
                                                                                        quemli + zim + gem/nab-pac vs. quemli + gem/nab-pac
                                        
Phase 1
Phase 1b
                                            
Phase 2
Phase 3
Indication:PDAC
Study:
                                                        
Line & Regimen:

                                            2L
                                                                                            
                                                                                        quemli + zim + gem/nab-pac
                                        
Phase 1
Phase 1b
                                            
Phase 2
Phase 3

Molecule^a,b,c :

Etrumadenant
(ETRUMA)

Dual A_2a/A_2b Adenosine Receptor Antagonist Small Molecule

Indication:NSCLC
Study:
                                                
Line & Regimen:
                                    1L, PD-L1 ≥ 50%
                                                                            
                                                                        dom + zim ± etruma vs. zim
                                
Phase 1
Phase 1b
                                    
Phase 2
Phase 3
Indication:NSCLC
Study:
                                                        
Line & Regimen:

                                            1L, 2L
                                                                                            
                                                                                        dom ± zim ± etruma ± sacituzumab govitecan
                                        
Phase 1
Phase 1b
                                            
Phase 2
Phase 3
Indication:CRPC
Study:
                                                        
Line & Regimen:

                                            2L
                                                                                            
                                                                                        etruma + zim + doce vs. doce
etruma + sacituzumab govitecan ± zim
                                        
Phase 1
Phase 1b
                                            
Phase 2
Phase 3
Indication:CRC
Study:
                                                        
Line & Regimen:

                                            2L
                                                                                            
                                                                                        etruma + zim + FOLFOX* vs. FOLFOX*
                                        
Phase 1
Phase 1b
                                            
Phase 2
Phase 3
Indication:CRC
Study:
                                                        
Line & Regimen:

                                            3L
                                                                                            
                                                                                        etruma + zim + FOLFOX* vs. rego
                                        
Phase 1
Phase 1b
                                            
Phase 2
Phase 3

Molecule^a,b,c :

AB521

HIF-2𝛂 Inhibitor

Indication:

Healthy Participants

Study:

Line & Regimen:

AB521

Phase 1

Phase 1b

Phase 2

Phase 3

Indication:

Advanced Malignancies, Including RCC

Study:

Line & Regimen:

2L+
AB521

Phase 1

Phase 1b

Phase 2

Phase 3

Etrumadenant: Dual A_2aR/A_2bR Antagonist Small Molecule
Quemliclustat: CD73 Inhibitor Small Molecule
Domvanalimab: TIGIT mAb
Zimberelimab: PD-1 mAb

These molecules and their uses are investigational, have not been proven to be safe, and have not been approved by the U.S. Food and Drug Administration.

ABBREVIATIONS:
atezo: atezolizumab; bev: bevacizumab; carbo/pem: carboplatin/pemetrexed; doce: docetaxel; dom: domvanalimab; enza: enzalutamide; etruma: etrumadenant; gem/nab-pac: gemcitabine/nab-paclitaxel; nivo: nivolumab; pembro: pembrolizumab; PLD: pegylated liposomal doxorubicin; quemli: quemliclustat; rego: regorafenib; SOC: standard of care; zim: zimberelimab;

CRC=colorectal cancer; CRPC=castrate-resistant prostate cancer; GI=gastrointestinal; NSCLC=non-small cell lung cancer; PDAC=pancreatic ductal adenocarcinoma; RCC=renal cell carcinoma

PARTNERSHIPS & COLLABORATIONS:

(a) In May 2020, Arcus and Gilead announced a 10-year partnership to co-develop and co-commercialize next-generation cancer immunotherapies. The parties will co-develop Gilead-optioned programs globally, and will co-commercialize in the U.S., with Gilead commercializing outside of the U.S., subject to the rights of Arcus’s existing partners for such programs.

(b) In September 2017, Arcus and Taiho announced an option and license agreement. Taiho has an option to Arcus’s programs arising during the 5-year term for Japan and certain other Asian territories (excluding China).

Astra Zeneca logo (c) Arcus and AstraZeneca are collaborating on PACIFIC-8, a registrational Phase 3 clinical trial, to evaluate domvanalimab plus durvalumab (Imfinzi®) in unresectable Stage 3 NSCLC with curative intent, where durvalumab is standard of care.

^*+/- biologic, e.g. bevacizumab or biosimilar, will be included for all patients in whom it is not contraindicated.

DISCOVERY PIPELINE

Immuno-Oncology Target

Anti-CD39

Exo-nucleotidase

CD39 is a key enzyme in removing ATP from the tumor microenvironment; increased ATP may enhance the adaptive immune response against tumors.¹

Additional undisclosed targets.

Cancer Cell Intrinsic Target

AXL Inhibitor

Tyrosine kinase

AXL overexpression is associated with tumor resistance to chemotherapy and immunotherapy drugs.²

Additional undisclosed targets.

References: 1. Moesta et al. Targeting CD39 in Cancer. Nature Reviews Immunology volume 20, pages739–755 (2020). 2. Axelrod HD, Valkenburg KC, Amend SR, et al. AXL is a putative tumor suppressor and dormancy regulator in prostate cancer. Mol Cancer Res. 2019;17(2):356-369.

COMBINING TO CURE®

CLINICAL PIPELINE

DISCOVERY PIPELINE

Immuno-Oncology Target

Cancer Cell Intrinsic Target

COMBINING TO CURE^®